Crucell Files Financial Statements with Euronext for H1 2005 in Accordance with IFRS
30. September 2005 09:22 ET
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 30, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has filed its Condensed Interim Financial Statements...
Crucell Clarifies CFO Comment Made at UBS Conference
27. September 2005 10:10 ET
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 27, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) wishes to clarify a comment made by its Chief Financial Officer Leonard...
Crucell to Present at UBS Global Life Sciences Conference, New York, September 26
21. September 2005 08:08 ET
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 21, 2005 (PRIMEZONE) -- Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) has announced that its Chief Financial Officer, Leonard Kruimer, will present at the UBS Global Life...
Crucell Appoints Agents to Boost Asian Market Potential
20. September 2005 02:06 ET
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 20, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has entered into agreements with Pharma&Soft in...
Crucell Secures 2 Million Grant from Dutch Ministry of Economic Affairs to Discover Antibodies Against Antibiotic-Resistant Bacterial Infections
16. September 2005 02:11 ET
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 16, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has received a grant of up to 2 Million from the...
Crucell and Aeras Announce Progress in TB Vaccine Program
08. September 2005 04:37 ET
|
Crucell N.V.
LEIDEN, Netherlands, Sept. 8, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and Aeras Global TB Vaccine Foundation today announced the initiation of a...
Crucell and US Navy Sign Agreement to Test AdVac-based Vaccine Against Anthrax and Plague
17. August 2005 02:15 ET
|
Crucell N.V.
LEIDEN, Netherlands, Aug. 17, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a Cooperative Research and Development...
Crucell and DSM Announce PER.C6 Licensing Agreement with Chiron
16. August 2005 05:11 ET
|
Crucell N.V.
LEIDEN, Netherlands, Aug. 16, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they have...
Harvard and Crucell Receive $19.2 million NIH Grant to Develop Next-Generation AdVac-based Vaccines
01. August 2005 02:11 ET
|
Crucell N.V.
LEIDEN, Netherlands, Aug. 1, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (Nasdaq:CRXL) announced today that it has, in collaboration with Harvard Medical School,...
Crucell Announces Second Quarter 2005 Results
18. Juli 2005 09:34 ET
|
Crucell N.V.
-- Increased development activity drives 34% growth in revenues for
first half-year.
-- New West Nile virus antibody discovered.
-- May 10th capital raising provides funds for further...